Skip Ribbon Commands
Skip to main content
Prof Lim Wan Teck Darren

Prof Lim Wan Teck Darren

MBBS (S’pore), MRCP (UK), FAMS

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology, Medical Oncology

Clinical Interest: Head & Neck, Thoracic-Oncology, Chest (Thoracic-Oncology), Lung, Nasopharynx, Thyroid

Conditions Treated by this Doctor:
Head and Neck Cancer, Larynx Cancer, Lung Cancer, Nasopharyngeal Cancer (Nose Cancer), Oral Cancer, Salivary Gland Cancer, Thyroid Cancer.

Clinical Appointments

  • Director (Research) SingHealth Duke-NUS Lung Centre
  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Professor


Prof Darren Lim is a Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore. His research interests are in nasopharyngeal, lung, thyroid, and head and neck squamous cancers with focus on clinical trials and biological correlates.


  • MBBS 
  • MRCP (UK) 

Professional Appointments and Committee Memberships

  • Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore 
  • Director, Investigational Medicine Unit, SingHealth 
  • Associate Professor, Office of Clinical Sciences, Duke-NUS Medical School
  • Director of Research, Department of Medical Oncology, National Cancer Centre Singapore 
  • International Association for the Study of Lung Cancer, Member 
  • American Society of Clinical Oncology, Member 
  • Singapore Society of Oncology, Member 
  • Academy of Medicine Singapore, Fellow


  • 2017 Ministry of Health National Clinician Scientist Award
  • 2012 Ministry of Health National Clinician Scientist Award
  • 2004 Ministry of Health Manpower Development Award

Research Interests

  • Nasopharyngeal cancer
  • Lung cancer
  • Head and Neck cancer


1. C. Even, H-M. Wang, S-H. Li, R. Ngan, A. Dechaphunkul, L. Zhang, C. J. Yen, P. C. Chan, S. Chakrabandhu, B. Ma, S. Tanasanvimon, V. Lee, P-J. Lou, Z. Li, A. Spira, A. Sukari, J. Guigay, S. McCune, J. Gonzalez-Maffe, S. Szpakowski, Y. Yao, H. Liang, J. Mataraza, R. Séchaud, L. Manenti,D.  W-T. Lim.  Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer. Clinical Cancer Re-search 2021; 27(23):6413-6423
2. Say Li Kong, Xingliang Liu, Swee Jin Tan, Joyce A Tai, Ler Yee Phua, Huay Mei Poh, Trifanny Zhi Xiang Yeo, Yong Wei Chua, Yu Xuan Haw, Wen Huan Ling, Raymond Chee Hui Ng, Tira Tan, Kiley Wei Jen Loh, Daniel Shao Weng Tan, Quan Sing Ng, Mei Kim Ang, Chee Keong Toh, Yi Fang Lee, Chwee Teck Lim, Tony Kiat Hon Lim, Axel M Hillmer, Yoon Sim Yap, Wan-Teck Lim  Complementary sequential circulating tumour cell (CTC) and cell-free tumour DNA (ctDNA) profiling reveals metastatic heterogeneity and genomic changes in lung cancer and breast cancer.  Frontiers in Oncology 2021; 11:698551-N.A.
3. Ang Mei-Kim; Montoya Jose Enrique; Tharavichitkul Ekkasit; Lim Cindy; Tan Ter-ence; Wang Lan Ying; Wee Joseph; Soong Yoke-Lim; Fong Kam-Weng; Ng Quan Sing; Tan Daniel Shao-Weng; Toh Chee-Keong; Tan Eng-Huat; Lim Wan-Teck. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cispla-tin/radiotherapy in patients with locally advanced head and neck squamous cell car-cinoma. Head & neck 2021; 43(5):1641-1651
4. Y Teng, HS Quah, DSW Tan, DWT Lim, NG Iyer.  Analysis of T-cell receptor clono-types in tumor micro-environment identifies shared cancer type-specific signatures. Cancer Immunology, Immunotherapy 2021;1-10
5. Y Belotti, SB Lim, NG Iyer, WT Lim, CT Lim.  Prognostic Matrisomal Gene Panel and Its Association with Immune Cell Infiltration in Head and Neck Carcinomas.  Can-cers 2021; 13(22):5761-NA
6. Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, Rahma O, Lesokhin A, Luke JJ, Otero J, Nardi L, Singh A, Xyrafas A, Chen X, Mataraza J, Bedard PL. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with ad-vanced solid tumors and lymphomas. J Immunother Cancer. 2021 Aug;9(8):e002863. doi: 10.1136/jitc-2021-002863.
7. Naoyuki Nogami, Fabrice Barlesi, Mark A Socinski, Martin Reck, Christian A Thom-as, Federico Cappuzzo, Tony SK Mok, Gene Finley, Joachim G Aerts, Francisco Or-landi, Denis Moro-Sibilot, Robert M Jotte, Daniil Stroyakovskiy, Liza C Villaruz, Delvys Rodríguez-Abreu, Darren Wan-Teck Lim, David Merritt, Shelley Coleman, Anthony Lee, Geetha Shankar, Wei Yu, Ilze Bara, Makoto Nishio.  IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups with EGFR Mutations or Metastases in the Liver or Brain. Journal of Thoracic Oncology 2021
8. GC Chang, DCL Lam, CM Tsai, ...WT Lim, V Sriuranpong, RTT Chan, RM Lorence, P Carriere, C Raabe, A Cseh, Park. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung can-cer who had progressed following prior therapies. International journal of clinical oncology 26 (5), 841-850, 2021.
9. Huang L, Zhang X, Chua KLM, Xie Y, Shu X, Long B, Fan C, Lim DWT, Tan SH, Wee JTS, Wang Y, Wu Y, Chua MLK.  Efficacy and safety of apatinib in recur-rent/metastatic nasopharyngeal carcinoma: a pilot study.  Oral Oncology 2021; 115:105222-N.A.
10. Biju Thomas, Mariko Siyue Koh, Christopher O’Callaghan, John Carson Allen Jr, Andrew Rutman, Robert Anthony Hirst, John Connolly, Su Ying Low, Ong Thun How, Loo Chian Min, Wan Teck Lim, Lynette Lin Ean Oon, Qixian He, Oon Hoe Teoh & Therese Sophie Lapperre.  Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD).  COPD: Journal of Chronic Ob-structive Pulmonary Disease 2021; 10.1080/15412555.2021.1963695:NA-NA
11. Stephanie PL Saw, Siqin Zhou, Jianbin Chen, Gillianne Lai, Mei-Kim Ang, Kevin Chua, Ravindran Kanesvaran, Quan Sing Ng, Amit Jain, Wan Ling Tan, Tanujaa Rajasekaran, Darren WT Lim, Aaron Tan, Kam Weng Fong, Angela Takano, Xin Ming Cheng, Kiat Hon Lim, Tina Koh, Boon-Hean Ong, Eng Huat Tan, Chee Keong Toh, Anders J Skanderup, Sze Huey Tan, Daniel SW Tan.  Association of Clinico-pathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer.  JAMA Network Open 2021; 4(11):e2131892-e2131892
12. AO Seet, AC Tan, T Tan, ... WT Lim, EH Tan, TKH Lim, DSW Tan. Individualized Mo-lecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. JCO Precision Oncology 5, 859-875, 2021
13. Khi Pin Chua, Yvonne H.F. Teng, Aaron C. Tan, …Wan-Teck Lim, …Axel M. Hillmer, Anders J. Skanderup and Daniel S.W. Tan. Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Thera-peutic Opportunities. Clin Cancer Res October 8 2021 DOI: 10.1158/1078-0432.CCR-20-4607
14. Mai, Hai-Qiang; Chen, Qiu-Yan; Chen, Dongping;… Lim, Wan-Teck, al. Toripal-imab or placebo plus chemotherapy as first-line treatment in advanced nasopharyn-geal carcinoma: a multicenter randomized phase 3 trial. Nature Medicine, 2021. DOI: 10.1038/S41591-021-01444-0
15. Lim, Darren Wan-Teck; Ng, Dorothy Hui Lin; Low, Jenny Guek-Hong. Bacillus Calmette-Guerin scar flare after an mRNA SARS-CoV-2 vaccine. Canadian Medical Association Journal, 2021. DOI: 10.1503/CMAJ.210696
16. Shuai Zhu, Shikang Zhao, Qian Zhang, Shuo Li, Dian Ren, Fan Ren, Lingling Zu, Yanye Wang, Xi Lei, Ning Zhou, Tao Shi, Dongbo Xu, Gang Chen, Wan-Teck Lim, Raffaele Giusti, Abraham J. Wu, Song Xu.  Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report.  Translational Lung Cancer Re-search 2021; N.A:N.A-N.A
17. Darren Wan Teck Lim, Quan Sing Ng.  The case for better hospitalisation selection in cancer patients.  Annals Academy of Medicine Singapore 2021; 50(12):880-881

Research Trials

  • A phase II, open-label, randomized, controlled study of PDR001 in patients with moderately undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment, 2016 
  • A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7), 2015 
  • A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of MPDL3280A (Anti-PDL1 Antibody) in combination with carboplatin+paclitaxel or MPDL3280A in combination with carboplatin+nab-paclitaxel versus carboplatin+nab-paclitaxel in chemotherapy-naive patients with stage IV squamous non-small cell lung cancer, 2015 
  • A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015